Pfizer/BioNTech trial shows long-term effect for young teens

    Its COVID-19 vaccine provided strong long-term protection against the virus, according to Pfizer Inc, in a study conducted among young adolescents with ages ranging from 12 to 15.

    MANILA, Philippines — The company said that having a two-dose series of the vaccine is 100% effective against COVID-19, measured seven days through four months after the second dose.

    Pfizer and BioNTech announced that the long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

    Pfizer notes that there are no serious safety concerns observed during the trial and side effects were in line with the other data reported for the vaccine. (JE/The MiNT)

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here